Company Statements
Filter By Year
September 28, 2023
September 26, 2023
Gilead Statement on the Discontinuation of Magrolimab Study in AML with TP53 Mutations
July 22, 2023
Gilead Statement on New York Times’ Story on TDF and TAF Development for HIV
June 30, 2023
Gilead Prevails in HIV Antitrust Trial
May 09, 2023
Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation
April 03, 2023
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
March 30, 2023
Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries
February 17, 2023
Christi Shaw to Depart Gilead and Kite Leadership End of Q1
February 09, 2023
Filter By Year
Some of the content on this page is not intended for users outside